Clinical Research Directory

Inclusion Criteria: Arms I-IV * Meet criteria for intermediate risk or high risk (BCG naïve, BCG exposed or BCG unresponsive disease) * English speakers * 18 years of age or older * Ability to understand and the willingness to provide an informed consent * Pathology documentation from any hospital/clinic/medical center, and * Predominant urothelial carcinoma histology in the specimen * Patients undergoing any treatment including observation are eligible for inclusion * Patients enrolling on clinical trial are eligible for participation * Any patient previously meeting criteria for BCG unresponsiveness who has a recurrence will be eligible for trial in category of BCG unresponsiveness even if last BCG was more than 1 year ago Arm V: * Diagnosed with stage II-IIIB muscle-invasive bladder cancer without evidence of distant metastases * 18 years of age or older * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to understand and the willingness to provide an informed consent * Histologically confirmed urothelial carcinoma of the bladder * The patient is deemed a candidate for and plans to undergo radical cystectomy Exclusion Criteria: Arms I-IV * Any plasmacytoid or small cell (neuroendocrine) component in the pathology (past or current presentation) * Previous history of cystectomy or radiation therapy for bladder cancer * Previous history of muscle-invasive bladder cancer or metastatic bladder cancer * Untreated upper tract urothelial carcinoma * Incarcerated in a detention facility or in police custody (patients wearing a monitoring device can be enrolled) at baseline/screening * Unable to provide written informed consent * Unable to be contacted for research surveys * Unable to provide Pathology documentation from any hospital/clinic/medical center * Unable to answer patient questionnaires Arm V: * Evidence of metastatic disease at enrollment * Any small cell (neuroendocrine) component in the pathology (past or current presentation) * Prior history of radiation therapy for bladder cancer * Inability or unwillingness to undergo radical cystectomy (e.g., patient opts for primary trimodality therapy). * Prior systemic therapy for urothelial carcinoma, unless it is the NAT for the current MIBC diagnosis. * Untreated upper tract urothelial carcinoma. * Unable to provide written informed consent. * Not willing or able to adhere with the study procedures * Active secondary malignancy * Diagnosis of a malignancy within 3 years of bladder cancer diagnosis, with the exception of low-risk prostate cancer managed with active surveillance, small renal cell carcinoma managed with active surveillance, and skin cancer managed with active surveillance